Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Univariate and multivariate associations with late grade 3 genitourinary toxicity

From: Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer

Variables Associated level Late grade 3 GU toxicity
   Hazard ratio (95% CI) p-value
Univariate analysis    
Age (years) Continuous 1.031 (0.921-1.154) 0.596
Risk group* Intermediate 0.659 (0.079-5.481) 0.699
Prostate volume# Continuous 0.928 (0.835-1.032) 0.170
Number of Applicators Continuous 1.247 (0.906-1.718) 0.176
PTV volume (cm3) Continuous 1.014 (0.974-1.056) 0.504
PTV V100 (%) Continuous >1000 (0.000- > 1000) 0.371
PTV D90 (Gy) Continuous 83.476 (0.019- > 1000) 0.301
Urethral volume (cm3) Continuous 41.143 (2.754-614.621) 0.007
Urethral D1 (Gy) Continuous 6.946 (0.000- > 1000) 0.692
Urethral V100 (cm3) Continuous 183.29 (6.785- > 1000) 0.002
Urethral V120 (cm3) Continuous 926.461 (2.653- > 1000) 0.022
Urethral V125 (cm3) Continuous 405.747 (0.249- > 1000) 0.111
Acute grade 3 GU toxicity Yes 7.846 (0.876-70.307) 0.066
Multivariate analysis    
Urethral volume (cm3) Continuous 338.940 (9.502- > 1000) 0.001
Urethral V100 (cm3) Continuous -  
Urethral V120 (cm3) Continuous 5778.111 (14.398- > 1000) 0.005
Acute grade 3 GU toxicity Yes -  
  1. Abbreviations: GU genitourinary, PTV planning target volume, PTV V 100 percentage of PTV receiving ≥100% of prescribed dose, D 90 dose administered to 90% of the PTV, Urethral V 100 -V150 absolute urethral volume that received a dose ≥100%, 120%, 125%, 150% of the prescribed dose, Urethral D 1 maximal dose that encompass 1% of the urethral volume, *according to the National Comprehensive Cancer Network ( NCCN), #pre-treatment, ADT androgen deprivation therapy.